STOCK TITAN

Tyra Biosciences (TYRA) awards CFO Alan Fuhrman RSUs and 67,000 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tyra Biosciences, Inc. granted Chief Financial Officer Alan Fuhrman new equity awards on May 5, 2026. He received 20,000 restricted stock units, which vest in four equal annual installments starting on May 5, 2027, each RSU representing one share of common stock. He was also granted options on 67,000 shares of common stock at an exercise price of $33.93 per share, vesting monthly over four years and expiring on May 4, 2036. Following these awards, he directly owns 36,164 shares of common stock, including RSUs.

Positive

  • None.

Negative

  • None.
Insider Fuhrman Alan
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 67,000 $0.00 --
Grant/Award Common Stock 20,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 67,000 shares (Direct, null); Common Stock — 36,164 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Includes RSUs. 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
RSUs granted 20,000 units Granted May 5, 2026; vest 1/4 annually over four years
Stock options granted 67,000 options at $33.93 Granted May 5, 2026; expire May 4, 2036
Shares owned after transaction 36,164 shares Common stock directly owned after May 5, 2026 grants, including RSUs
Option vesting schedule 1/48 vests monthly Monthly vesting following May 5, 2026 over four years
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted on May 5, 2026."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting commencement date financial
"anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
continuous service financial
"vest on each of the first four anniversaries ... subject to the Reporting Person's continuous service through each vesting date."
exercise price financial
"shares subject to the option vest monthly following May 5, 2026, the vesting commencement date"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
expiration date financial
"Stock Option (Right to Buy) ... expiration_date: 2036-05-04"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fuhrman Alan

(Last)(First)(Middle)
C/O TYRA BIOSCIENCES, INC.
2656 STATE STREET

(Street)
CARLSBAD CALIFORNIA 92008

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026A20,000(1)A$036,164(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$33.9305/05/2026A67,000 (3)05/04/2036Common Stock67,000$067,000D
Explanation of Responses:
1. Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
2. Includes RSUs.
3. 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
/s/ Ali D. Fawaz, Attorney-in-Fact05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did TYRA grant to its CFO Alan Fuhrman?

Tyra Biosciences granted CFO Alan Fuhrman 20,000 restricted stock units and options on 67,000 shares of common stock. The RSUs vest annually over four years, while the options vest monthly over four years at a $33.93 exercise price.

How do Alan Fuhrman’s TYRA restricted stock units vest?

The 20,000 RSUs granted to Alan Fuhrman vest in four equal annual installments. One quarter vests on each of the first four anniversaries of May 5, 2026, assuming he continues to provide service through each vesting date.

What are the terms of Alan Fuhrman’s TYRA stock options?

Alan Fuhrman received options on 67,000 TYRA shares with a $33.93 exercise price. One forty-eighth of the options vest monthly after May 5, 2026, over four years, and the options expire on May 4, 2036, subject to continued service.

How many TYRA shares does Alan Fuhrman own after these grants?

After the May 5, 2026 equity grants, Alan Fuhrman directly owns 36,164 shares of Tyra Biosciences common stock. This figure includes shares represented by his restricted stock units, reflecting his updated direct ownership position.

Are Alan Fuhrman’s TYRA RSUs equivalent to common stock today?

The RSUs are not current shares but rights to receive common stock later. Each restricted stock unit represents one future TYRA common share, issuable only as the RSUs vest and other grant conditions, such as continued service, are satisfied.

What conditions apply to vesting of TYRA awards granted to the CFO?

Both the RSUs and stock options require continuous service to Tyra Biosciences. RSUs vest annually on each of the first four anniversaries of May 5, 2026, while the options vest monthly over four years, each schedule conditioned on ongoing service.